Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17704913 | 0.93 | KCNH2 (0.40) | KCNH2AOC3GSK3BDYRK1ACYP19A1 | |
| SCHEMBL14875848 | 0.88 | AOC3 (0.42) | KCNH2AOC3GSK3BDYRK1ACYP11B2 | |
| SCHEMBL14875496 | 0.88 | AOC3 (0.48) | AOC3GSK3BDYRK1ACNR1CYP11B2 | |
| SCHEMBL12327711 | 0.88 | KHK (0.46) | KCNH2AOC3GSK3BDYRK1ACYP11B2 | |
| SCHEMBL14780472 | 0.86 | AOC3 (0.38) | AOC3GSK3BDYRK1ACYP11B2KHK | |
| SCHEMBL14875442 | 0.86 | PRKDC (0.39) | AOC3GSK3BDYRK1ACNR1CYP11B2 | |
| SCHEMBL14786014 | 0.85 | KCNH2 (0.56) | KCNH2AOC3CYP19A1CNR1CYP11B2 | |
| SCHEMBL14875457 | 0.85 | CYP19A1 (0.41) | AOC3GSK3BDYRK1ACYP19A1CYP11B2 | |
| SCHEMBL22997030 | 0.84 | KCNH2 (0.42) | KCNH2AOC3CNR1CYP11B2 | |
| SCHEMBL22819136 | 0.83 | KCNH2 (0.40) | KCNH2CYP19A1CNR1CYP11B2KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| WO-2015189534-A1 | VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY | PROXIMAGEN LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
| EP-2927233-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014199171-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-12-18 | — | — | WO | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| EP-2547677-A2 | INHIBITORS OF SEMICARABAZIDE - SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113798-A2 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | KCNH2 3747/4885AOC3 24/4885GSK3B 3629/4885 |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | SERPINB1, SSB, NFKBIA | KCNH2 4480/4885AOC3 154/4885GSK3B 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.